Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Burkholderia Infections

ClinicalTrials.gov lists 18 trials for Burkholderia Infections or a narrower condition beneath it.

MeSH D019121 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 1 Phase 4 Phase 4 2 Not applicable Not applicable 3 Observational Observational 8 Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 1 Phase 4 Phase 4 2 Not applicable Not applicable 3 Observational Observational 8

Trials per phase

5 of the 18 trials are tagged with Burkholderia Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Burkholderia Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Burkholderia Infections trials start? (14)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 2

2007: 1 trials (Not applicable 1) 2010: 1 trials (Phase 3 1) 2011: 1 trials (Phase 4 1) 2013: 1 trials (Not applicable 1) 2014: 2 trials (Not applicable 1, Phase 1 1) 2015: 1 trials (Phase 2 1) 2016: 1 trials (Observational 1) 2017: 2 trials (Observational 1, Phase 1 1) 2018: 2 trials (Observational 2) 2019: 1 trials (Observational 1) 2022: 1 trials (Phase 2 1) 2023: 2 trials (Observational 1, Phase 4 1) 2025: 1 trials (Observational 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 1
2023 2
2022 1
2019 1
2018 2
2017 2
2016 1
2015 1
2014 2

No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Burkholderia Infections trials in? (6)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 2 2
Phase 3 1
Phase 4 2
Not applicable 3
Observational 8

How many Burkholderia Infections trials are recruiting? (4)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 2
Completed 12
Terminated 1
Unknown status 3

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Burkholderia Infections trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AN2 Therapeutics, Inc 1
AlgiPharma AS 1
Arrevus Inc. 1
Gilead Sciences 1
Synspira, Inc. 1

Which drugs are being tested for Burkholderia Infections? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ceftazidime 1

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
I.V. Meropenem 1
tobramycin / TOBI 1
Ceftolozane-Tazobactam 1
AZLI 1
Ceftazidime or meropenem 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Burkholderia Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Lung disorder 39 1
Infective pulmonary exacerbation of cycstic fibrosis 35 1
Haemoptysis 5 1
Pneumonia 3 1
Chest pain 2 1

Which publications cover Burkholderia Infections? (15)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transplant infectious disease : an official journal of the Transplantation Society 2023 Yes
Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2022 Yes
Phenotypic and Genomic Analyses of Burkholderia stabilis Clinical Contamination, Switzerland. Emerging infectious diseases 2019 Yes
Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2017 Yes
<i>Burkholderia stabilis</i> outbreak associated with contaminated commercially-available washing gloves, Switzerland, May 2015 to August 2016. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2017 Yes

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages